Skip to main content

Table 3 Multivariate analysis of overall survival (OS) and progression-free survival (PFS) for patients diagnosed with Waldenström macroglobulinemia (WM) with extramedullary involvement (EMWM)

From: Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis

  OS   PFS
Variable HR 95 % CI P a Variable HR 95 % CI P a
EMWM
Age ≥65 years 1.41 0.67–2.97 0.367 Race (white) 0.50 0.25–1.00 0.051
IPSSWM (I, II vs III) 1.41 0.90–2.21 0.138 IgM >7000 mg/L 0.42 0.15–1.16 0.094
ALB <3.5 g/dL 2.09 1.07–4.07 0.031 Cytogenetic (abnormal) 1.86 1.09–3.17 0.022
BM involvement 0.99 0.98–1.00 0.080 - - - -
WM
Age ≥65 years 3.13 1.85–5.29 <0.001 Race (white) 0.57 0.32–1.05 0.070
Hb ≤11.5 g/L 1.12 0.65–1.93 0.685 IgM >7000 mg/L 0.49 0.23–1.04 0.064
B symptom–positive 1.25 0.72–2.17 0.428 Cytogenetic (abnormal) 1.78 1.21–2.63 0.003
EM–positive 4.28 2.42–7.55 <0.001 EM–positive 2.06 1.39–3.06 <0.001
PLT <100 × 109/L 1.14 0.63–2.05 0.663 PLT <100 × 109/L 0.98 0.60–1.59 0.935
ALB <3.5 g/dL 2.10 1.24–3.54 0.006 ALB <3.5 g/dL 1.12 0.69–1.80 0.648
LDH >618 IU/L 2.00 0.98–4.06 0.054 LDH >618 IU/L 1.47 0.87–2.51 0.153
β2-MG >3 mg/L 1.36 0.78–2.38 0.277 β2-MG >3 mg/L 1.42 0.92–2.17 0.111
  1. CI confidence interval, HR hazard ratio, IPSSWM International Prognostic Scoring System for WM, IgM immunoglobulin M, ALB albumin, BM bone marrow, Hb hemoglobin, PLT platelet, LDH lactate dehydrogenase, β2-MG beta-2 microglobulin level
  2. a P value by Cox proportional hazards regression model; statistically significant values appear in italics